Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.

---

Copy For Citation

Ucan Gunduz G., Yalcinbayir O., Cekic Ş., Yildiz M., Kilic S. Ş.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, vol.37, no.4, pp.236-240, 2021 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 37 Issue: 4
• Publication Date: 2021
• Doi Number: 10.1089/jop.2020.0081
• Journal Name: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
• Page Numbers: pp.236-240
• Keywords: adalimumab, infliximab, noninfectious, pediatric, uveitis
• Bursa Uludag University Affiliated: Yes

Abstract

Purpose: Management of uveitis displays a particular challenge in childhood. This study aims to compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in pediatric noninfectious uveitis that were refractory to conventional immunosuppresives.